Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced an exploratory collaboration with a leading luxury skin care company to explore opportunities for its patented INTASYL compound in cosmeceutical applications. This collaboration aims to leverage Phio's gene silencing technology for aging skin disorders. CEO Robert Bitterman highlighted the significance of this step in demonstrating INTASYL's versatility across multiple applications.
Phio's INTASYL patent portfolio now includes 77 issued patents covering the silencing of over 25 gene targets in various fields, including dermatology, immuno-oncology, ophthalmology, and viral disorders. The technology is designed to enhance the effectiveness of immune cells in killing tumor cells, with applications for both intratumoral treatment and adoptive cell therapy.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ha annunciato una collaborazione esplorativa con una prestigiosa azienda di bellezza per esaminare opportunità per il suo composto brevettato INTASYL nelle applicazioni cosmeceutiche. Questa collaborazione mira a sfruttare la tecnologia di silenziamento genico di Phio per i disordini della pelle legati all'invecchiamento. Il CEO Robert Bitterman ha sottolineato l'importanza di questo passo nel dimostrare la versatilità di INTASYL in molteplici applicazioni.
Il portafoglio brevetti di INTASYL di Phio include ora 77 brevetti rilasciati che coprono il silenziamento di oltre 25 bersagli genetici in vari campi, tra cui dermatologia, immuno-oncologia, oftalmologia e disturbi virali. La tecnologia è progettata per migliorare l'efficacia delle cellule immunitarie nell'uccidere le cellule tumorali, con applicazioni sia per il trattamento intratumorale che per la terapia cellulare adottiva.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ha anunciado una colaboración exploratoria con una destacada empresa de cuidado de la piel de lujo para explorar oportunidades para su compuesto patentado INTASYL en aplicaciones cosmeceúticas. Esta colaboración tiene como objetivo aprovechar la tecnología de silenciado génico de Phio para los trastornos cutáneos relacionados con la edad. El CEO Robert Bitterman destacó la importancia de este paso para demostrar la versatilidad de INTASYL en múltiples aplicaciones.
El portafolio de patentes de INTASYL de Phio ahora incluye 77 patentes emitidas que cubren el silenciado de más de 25 objetivos genéticos en varios campos, incluyendo dermatología, inmuno-oncología, oftalmología y trastornos virales. La tecnología está diseñada para mejorar la efectividad de las células inmunitarias en la eliminación de células tumorales, con aplicaciones tanto para el tratamiento intratumoral como para la terapia celular adoptiva.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO)는 유명한 럭셔리 스킨케어 회사와의 탐색적 협력을 발표하며, 자사의 특허받은 INTASYL 화합물을 코스메슈티컬 적용에 대한 기회를 모색합니다. 이 협력은 노화 피부 질환에 대한 Phio의 유전자 침묵 기술을 활용하는 것을 목표로 하고 있습니다. CEO 로버트 비터맨은 INTASYL의 다재다능성을 여러 응용 분야에서 입증하는 데 있어 이 단계의 중요성을 강조했습니다.
Phio의 INTASYL 특허 포트폴리오는 현재 77개의 발행된 특허를 포함하며, 피부과, 면역 종양학, 안과 및 바이러스 질환 등 다양한 분야에서 25개 이상의 유전자 표적의 침묵을 다루고 있습니다. 이 기술은 종양 세포를 제거하는 면역 세포의 효능을 향상시키는 데 설계되었으며, 종양 내 치료 및 채택된 세포 치료에 대한 응용이 가능합니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a annoncé une collaboration exploratoire avec une entreprise de soins de la peau de luxe reconnue pour explorer les opportunités offertes par son composé breveté INTASYL dans les applications cosméceutiques. Cette collaboration vise à tirer parti de la technologie de silençage génétique de Phio pour les troubles cutanés liés à l'âge. Le PDG Robert Bitterman a souligné l'importance de cette étape pour démontrer la polyvalence d'INTASYL dans différentes applications.
Le portefeuille de brevets d'INTASYL de Phio comprend désormais 77 brevets délivrés couvrant le silençage de plus de 25 cibles génétiques dans divers domaines, dont la dermatologie, l'immuno-oncologie, l'ophtalmologie et les troubles viraux. Cette technologie est conçue pour améliorer l'efficacité des cellules immunitaires dans la destruction des cellules tumorales, avec des applications tant pour le traitement intratumoral que pour la thérapie cellulaire adoptive.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) hat eine explorative Zusammenarbeit mit einem führenden Luxus-Hautpflegeunternehmen angekündigt, um Möglichkeiten für seine patentierte INTASYL-Verbindung in der Kosmetik zu erkunden. Diese Zusammenarbeit zielt darauf ab, Phios Gen-Silencing-Technologie für Hautalterungsstörungen zu nutzen. CEO Robert Bitterman wies auf die Bedeutung dieses Schrittes hin, um die Vielseitigkeit von INTASYL in verschiedenen Anwendungen zu demonstrieren.
Phios INTASYL-Patentportfolio umfasst jetzt 77 erteilte Patente, die das Silencing von über 25 Genzielen in verschiedenen Bereichen, einschließlich Dermatologie, Immunonkologie, Augenheilkunde und Viruskrankheiten, abdecken. Die Technologie ist darauf ausgelegt, die Effektivität von Immunzellen beim Abtöten von Tumorzellen zu verbessern, mit Anwendungen sowohl für die intratumorale Behandlung als auch für die adoptive Zelltherapie.
- Exploratory collaboration with a leading luxury skin care company
- Potential expansion into cosmeceutical applications
- INTASYL patent portfolio includes 77 issued patents
- Technology covers silencing of over 25 gene targets in multiple fields
- None.
Insights
Phio Pharmaceuticals' exploratory collaboration with a luxury skin care company marks an intriguing expansion of their INTASYL technology into the cosmeceutical market. While this move showcases the versatility of their platform, it's important to note that this is still in the early exploratory phase.
The company's 77 issued patents covering multiple therapeutic areas demonstrate a robust intellectual property portfolio. However, investors should be cautious as commercialization in the cosmeceutical space may require different expertise and regulatory pathways compared to Phio's core focus in immuno-oncology.
This collaboration could potentially open up new revenue streams if successful, but it's too early to quantify the impact. The lack of specific financial terms or timelines in the announcement suggests this is still a preliminary arrangement. Investors should monitor for future updates on concrete development plans or financial commitments from the luxury skin care partner.
The global luxury skincare market is projected to reach
However, the competitive landscape is fierce, dominated by established players with strong brand recognition and extensive distribution networks. Phio's success will depend on:
- The efficacy of INTASYL in addressing aging skin concerns
- The luxury partner's ability to market and differentiate the technology
- Regulatory approval processes for cosmeceutical applications
While this move diversifies Phio's potential revenue streams, investors should note that success in the cosmeceutical market doesn't guarantee success in their core therapeutic areas. The company will need to balance resources between this new venture and their primary focus on immuno-oncology to maximize shareholder value.
Phio's INTASYL compound targets aging skin disorders
Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that they have entered into an exploratory collaboration regarding opportunities for the recently issued Phio patent for cosmeceutical skin care applications.
The collaborating company is one of the leading companies in luxury skin care products that are commercialized world-wide.
"This is a significant step in demonstrating the potential versatility of INTASYL across multiple applications," said Robert Bitterman, CEO of Phio Pharmaceuticals. "The INTASYL patent portfolio now consists of 77 issued patents for silencing over 25 gene targets in the fields of dermatology, immuno-oncology, ophthalmology, and viral disorders, both intratumorally and in adoptive cell therapy."
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for specialized formulations or drug delivery systems. INTASYL drugs precisely down regulate specific proteins that inhibit the body's ability to overcome chronic diseases and other disorders.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218930
FAQ
What is the purpose of Phio Pharmaceuticals' collaboration with the luxury skin care company?
How many patents does Phio Pharmaceuticals (PHIO) currently hold for its INTASYL technology?
What are the main application areas for Phio Pharmaceuticals' (PHIO) INTASYL technology?
How does Phio Pharmaceuticals' (PHIO) INTASYL technology work?
